GSK Looks To Cross PD-1 Gap And Leap To Next-Generation IO Backbone
This article was originally published in Scrip
GlaxoSmithKline PLC isn't letting the fact that it doesn’t have a PD-1/L1 inhibitor get its immuno-oncology R&D efforts down. Instead, the company is focusing immuno-oncology research on next-generation checkpoint modulators, including the OX40 agonist antibody GSK3174998 and first-in-class ICOS agonist antibody GSK3359609, the company said during an R&D day in New York City Nov. 3.
Register for our free email digests: